Population | Indications (only if nirsevimab is not available) |
Preterm infants with BPD* |
|
Preterm infants without BPD |
|
Infants with CHD | Most likely to benefit:
May benefit:
|
Other potential candidatesΔ |
|
RSV: respiratory syncytial virus; BPD: bronchopulmonary dysplasia; GA: gestational age; CHD: congenital heart disease; TEF: tracheoesophageal fistula; SCID: severe combined immunodeficiency; HCT: hematopoietic cell transplant.
* BPD is variably defined. For the purpose of this table, we define BPD as GA <32 weeks and a requirement for supplementation oxygen for at least the first 28 days after birth.
¶ These risk factors plus out of pocket cost are taken into consideration on a case-by-case basis in consultation with the infant's caregiver(s).
Δ Use of palivizumab in these patient populations is not standardized and evidence is limited.Do you want to add Medilib to your home screen?